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Abstract
Background: Idiopathic male infertility is often treated empirically. A recent body of
evidence has indicated the association between pro ± prebiotics administration and
improvement in semen parameters.
Objective: To assess the effect of FamiLact (probiotic + prebiotic) administration on
male subjects with idiopathic infertility.
Materials and Methods: Fifty-six men with idiopathic male infertility were
randomly/equally divided into two groups. Men in the case and control groups
received 500 mg of FamiLact and an identical placebo for 80 days, respectively. A
semen sample was obtained from each of the participants before initiation and after
the termination of the treatment course. Samples underwent regular semen analysis
and were further analyzed to assess the level of DNA damage (sperm chromatin
structure assay), oxidative stress (BODIPY C11 staining), and protamine deficiency
(chromomycin-A3 staining) in spermatozoa.
Results: No significant difference was observed between the baseline values of both
groups. After intervention, mean sperm concentration, motility, and normal morphology
were significantly higher in the FamiLact group compared to the placebo group (p <
0.05). In the FamiLact receivers, we detected improvement regarding the following
parameters: concentration, motility, abnormal morphology, sperm lipid peroxidation,
and DNA fragmentation (p ≤ 0.02). Likewise, in the placebo group, we noticed a
decrease in the post-medication mean value of DNA fragmentation (p = 0.03) while
observing no significant difference regarding other parameters.
Conclusion: FamiLact administration improves sperm concentration, motility, and
abnormal morphology and decrease sperm DNA damage, possibly through alleviating
oxidative stress in the seminal fluid.
Key words: Male infertility, DNA fragmentation, Sperm, Synbiotics, Probiotics, Fertility
agents.
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1. Introduction
A male factor contributes to 40-50% of all
infertility cases and is the sole cause behind 20-
30% of them (1). Abnormality in semen parameters
leading to eventual sperm dysfunction is almost
unanimously inseparable from male infertility
etiologies. Today, the existing diagnostic
modalities fail to point out the exact origins
of abnormal semen parameters in a significant
proportion of cases, a condition addressed as
idiopathic male infertility (2). Although studies
have proposed numerous contributing factors,
they often share a common denominator:
seminal oxidative stress (OS) (3). In the seminal
plasma, disharmony between oxidizing agents
and reductant molecules (i.e., antioxidants)-
a state in which the former outbalances the
latter- precipitates OS (4). OS may take place
whether as a consequence of redundancy
in seminal reactive oxygen species (ROS),
generated dominantly by either sperm with
abnormal morphology or leukocytes, or due
to shortage in endo-/exogenous antioxidants
(4).
Idiopathic male infertility is often treated
empirically, employing hormonal and or
nonhormonal remedies. Nonhormonal therapies
commonly rely on oral supplementation with
antioxidant compounds, exerting beneficial
effects on sperm quality, pregnancy rate, live
birth rate, and spermic DNA damage [for a recent
review, check (5)]. Recently, performing random
semen analyses for three Flortec (probiotic +
prebiotic; Bracco, Italy) consumers diagnosed
with gastrointestinal dysbiosis, Maretti and
colleagues detected an unforeseen improvement
in their sperm quality (6), the observation
which prompted a pilot controlled clinical trial
to evaluate the efficacy of probiotic administration
on idiopathic oligoasthenoteratozoospermia.
Supplementation with Flortec led to a statistically
significant increase in the mean ejaculate
volume, sperm concentration, progressive
motility, and the percentage of morphologically
normal spermatozoa (6). In a simultaneous
attempt, Valcarce and colleagues underlined a
significant decrease in sperm DNA damage in
the medication period and an elevation in the
percentage of motile sperms following probiotic
administration on asthenozoospermic men
(7).
Probiotics are live microorganisms that if
administered adequately promote the host’s
well-being through various mechanisms, namely
reinforcing the epithelial barrier and modifying
the immune system (8). However, the mechanisms
by which probiotics favorably contribute to male
fertility are still arguable.
Pro-/prebiotic administration for male
fertility purposes is a relatively novel field
of research, and the existing evidence is
scarce. Opting FamiLact, we aimed to further
investigate the efficacy of supplementation
with synbiotic products in idiopathic male
infertility and the underlying mechanism(s).
FamiLact is a synbiotic product containing a
broad spectrum of beneficial Lactobacillus
strains, Bifidobacterium breve/longum, and
Streptococcus thermophiles accompanied
by fructooligosaccharides as the prebiotic.
Applying chromomycin A3 (CMA3) staining
technique, this is the first study to evaluate
the effects of such products on spermic DNA
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integrity by means of nuclear protamine content.
Moreover, recruiting a relatively larger sample
size compared to the pre-existing trials, we
targeted more pragmatic results regarding DNA
fragmentation.
2. Materials and Methods
2.1. Patient selection
Through this triple-blind, randomized, placebo-
controlled clinical trial, we selected the patients
from the infertile couples’ male partners, referred
to the Imam Reza Hospital (Tehran, Iran) between
November 2019 and May 2020. We defined
infertility as the failure to establish a clinical
pregnancy following 12 months of regular,
unprotected sexual intercourse (9). According
to the World Health Organization’s designated
cut-offs (10), men with sperm concentration <
15 (106/mL) and/or normal morphology < 4 (%)
and/or total motility < 40 (%) were considered
eligible to participate in the study (solely
addressed as oligozoospermia, teratozoospermia,
and asthenozoospermia, respectively). As
idiopathic male infertility is a diagnosis of
exclusion, men with the following conditions
were excluded from the study: cryptorchidism;
varicocele; chromosome abnormalities;
leukocytospermia; epididymal-orchitis; genito-
urinary traumas; prostatitis; testicular torsion;
history of inguinal/genital surgery; history of
hormone therapy; endocrinopathies; history
or ongoing use of cytotoxic drugs as well as
immunosuppressants, anticonvulsants, and
androgens; and recent history of sexually
transmitted infections.
2.2. Study design
Out of the 60 eligible patients, 56 met our
inclusion criteria and were randomly divided into
treatment (n = 28) and control (n = 28) groups.
While the subjects in the treatment group were
designated to receive a single capsule (500mg) of
FamiLact on a daily basis for 80 consecutive days,
the controls took the identical placebo (Figure
1) (11). FamiLact is formulated by Zist Takhmir
Pharmaceutical Company, under the permission
of the Food and Drug Department of Iran’s Ministry
of Health and Medical Education (reference no.:
0347756442342525). Each capsule of FamiLact
contains bacterial strains of Lactobacillus
rhamnosus, Lactobacillus casei, Lactobacillus
bulgaricus, Lactobacillus acidophilus,
Bifidobacterium breve, Bifidobacterium longum,
Streptococcus thermophilus (109 CFU), and
fructooligosaccharides as prebiotic.
Randomization was carried out utilizing
the permutation block method: a random
sequence on all possible permutations
was obtained (nine blocks containing
eight units). Drug and placebo, equal in
packing and weight, were given to the
participants according to the randomization
sequence.
Patients, healthcare providers, data collectors,
and statistical analysts were blinded to the
randomization sequence.
2.3. Sample collection and
conventional semen analysis
Two semen samples were retrieved from
each of the subjects before and 80 days
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after the onset of medication, provided by
masturbation following two-seven days of sexual
abstinence. Samples were left to liquefy in
the ambient temperature. A trained operator,
blinded to the medication sequence, fixed
and analyzed the samples according to the
World Health Organization’s instructions. Sperm
concentration was evaluated by applying a
Sperm Counting Chamber (Shivani Scientific
Industries, Mumbai, India), and motility was
assessed through a computer-assisted sperm
analysis system (Video Test, Version Sperm 2.1©,
Russia).
Diff-Quik, CMA3, and BODIPY staining
techniques were exerted to measure the
morphological alterations, level of protamination,
and lipid peroxidation status of the samples,
respectively. In addition, the DNA fragmentation
was evaluated by sperm chromatin structure
assay (SCSA).
2.4. Evaluating DNA fragmentation:
SCSA
After segregating 2 million sperms from the
samples, a buffer containing TNE/NaCl/EDTA was
added to the vessel to increase the volume to
1 mL. In the case tube, 400 μl acid-detergent
solution was added to 200 μl of the attenuated
semen sample and was later mixed with 1200
μl of acridine orange staining solution (Sigma,
St. Louis, USA), however, in the control tube
the first step was bypassed. Next, the level of
DNA fragmentation (percentage) was evaluated
using a FACSCalibur flow cytometer (Becton
Dickinson, San Jose, CA, USA). An approximate
number of 10,000 spermatozoa/sample were
analyzed.
2.5. Evaluating lipid peroxidation:
BODIPY probing
Nearly 2 million spermatozoa were isolated.
BODIPY 581/591 C11 probe (D3861, Molecular
Probes) [5 mM/ml] was added to the sample.
Acquired tubes were then incubated for 30 min
(37°C) followed by phosphate-buffered saline
wash out. The percentage of BODIPY-positive
spermatozoa (i.e., BODIPY-stained spermatozoa)
was reported applying a FACSCalibur flow
cytometer (Becton Dickinson, San Jose, CA, USA)
(12).
2.6. Evaluating protamine deficiency:
CMA3 staining
Obtained samples were washed applying
phosphate-buffered saline, followed by fixation
in Carnoy’s solution (methanol: glacial acetic
acid 3:1; Merck, Germany). After that, two
smears were provided and stained with
CMA3 solution for 20 min and washed
subsequently. For each sample, a minimum
of 300 sperm cells was counted using a
fluorescence microscope (Olympus BX51, Tokyo,
Japan) with 460-470 nm filters. Sperms with
bright yellow heads and the ones lacking
brightness (dim yellow) were considered as
CMA3-positive and -negative, respectively,
and their proportion was further reported as
percentages.
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Figure 1. Flow diagram of the study according to CONSORT 2010.
2.7. Ethical considerations
This study was approved by AJA University
of Medical Sciences Ethics Committee
(IR.AJAUMS.REC.1398.051). Our trial was
registered in the Iranian Registry of Clinical
Trials (IRCT20190824044599N1). In addition,
the course of the study was explained to all
participants, and a signed formal consent was
obtained from each of them.
2.8. Statistical analysis
Statistical analysis was performed utilizing
STATA v.13 (STATA Corp., Texas, USA) for Mac. We
evaluated the distributional status of the variables
drawing standardized normal probability plots.
As perceived normally distributed, the inter-
and intra-group comparison was done using
the classical t test (mean comparison test)
and paired t test, respectively. The calculated
p-values < 0.05 were considered significant.
All results were rendered as mean ± standard
deviation (SD).
3. Results
After allocation, seven participants failed to
attend the follow-up sampling. Additionally, one
patient discontinued due to the occurrence of
pregnancy and one declined consent, confining
our study population to 47 subjects consisting of
22 cases and 25 controls (Figure 1). Themean age
in the FamiLact and placebo groups was 34.5 and
33.8, respectively (p = 0.61).
As shown in Table I, the participants’
baseline sperm characteristics did not
show any statistically significant difference
comparing the two study groups. However,
in the endpoint semen samples, we noticed
a significant dominance in the case group
compared with the control group with respect
to the concentration (p = 0.01), motility (p =
0.04), and normal morphology (p = 0.03)
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(Table I). Paired t test analysis revealed a
significant favorable difference between
the mean pre-/post-medication values in
concentration (p = 0.004), motility (p = 0.003),
abnormal morphology (p = 0.014), sperm lipid
peroxidation (p = 0.02), and DNA fragmentation
(p = 0.005) in the FamiLact receivers (Table
II).
In contrast, the mean semen volume and
CMA3 positivity did not differ significantly
from the baseline measures. Likewise,
we observed a decreased mean DNA
fragmentation value in the placebo group after
medication (p = 0.03), while other parameters
showed no significant discrepancies (Figure
2).
Table I. Baseline and endpoint sperm characteristics of the participants
FamiLact (n = 22) Placebo (n = 25)Parameter
Before After Before After
Intergroup p-value
2.75 ± 1.46 2.97 ± 2.22 2.54 ± 1.18 2.54 ± 1.86 0.59𝑏Volume (ml)
P = 0.47𝑐 P = 0.97𝑐 0.23𝑎
28.85 ± 17.1 44.1 ± 24.97 21.54 ± 15.48 27.98 ± 17.42 0.13𝑏Concentration
P = 0.004𝑐 P = 0.06𝑐 0.01𝑎
38.4 ± 25.08 50.81 ± 34.94 33.54 ± 20.3 34.44 ± 30.31 0.46𝑏Motility (%)
P = 0.003𝑐 P = 0.39𝑐 0.04𝑎
86.62 ± 11.61 79.5 ± 5.54 85.25 ± 9.61 83.5 ± 8.21 0.66𝑏Abnormal morphology (%)
P = 0.01𝑐 P = 0.25𝑐 0.03𝑎
Data are presented as Mean ± SD, 𝑎Two sample t tests (comparing intergroup after-intervention values), 𝑏Two sample t tests
(comparing intergroup before-intervention values), 𝑐Paired t test (comparing intragroup before/after values)
Table II. Level of lipid peroxidation, protamine deficiency, and DNA damage before and after the intervention
FamiLact (n = 22) Placebo (n = 25)Parameter
Before After Before After
Intergroup p-value
29.53 ± 19.4 26 ± 18.82 26.32 ± 15.35 24.72 ± 15.91 0.53𝑏Sperm lipid peroxidation (%)
P = 0.02𝑐 P = 0.09𝑐 0.8𝑎
39.97 ± 12.83 34.33 ± 3.24 37.97 ± 10.18 33.67 ± 9.69 0.27𝑏CMA3 positivity (%)
P = 0.11𝑐 P = 0.14𝑐 0.76𝑎
28.81 ± 13.27 25.19 ± 7.22 26.75 ± 10.54 25.32 ± 6.66 0.55𝑏DNA fragmentation index (%) [SCSA]
P = 0.005𝑐 P = 0.03𝑐 0.47𝑎
Data are presented as Mean ± SD, 𝑎Two sample t tests (comparing intergroup after-intervention values), 𝑏Two sample
t tests (comparing intergroup before-intervention values), 𝑐Paired t test (comparing intragroup before/after values), CMA3:
Chromomycin A3, SCSA: Sperm chromatin structure assay
Figure 2. The effect of FamiLact supplementation vs placebo on the seminal OS, protamine deficiency, and DNA damage
indicators in men with idiopathic infertility. Data are presented as Mean ± SD (paired t test). LPx: Lipid peroxidation, CMA3+:
Chromomycin A3 positivity, DFI: DNA Fragmentation Index.
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4. Discussion
Through the course of this study, we aimed to
explore the effect of FamiLact supplementation
on sperm health. Our analysis indicated a
significant improvement in sperm concentration,
motility, abnormal morphology, and seminal
lipid peroxidation, as well as sperm chromatin
structure following 80 days of FamiLact
administration (500 mg/daily) in male subjects
with idiopathic infertility.
Intestinal microbiota, a vast number of specific
microorganisms preoccupying the human’s
gastrointestinal tract, favorably contribute to the
host’s well-being through various mechanisms:
reinforcing the epithelial barrier, competing
with pathogens for adhesion to the receptors,
regulating the immune system, and generating
vitamins as well as short-chain fatty acids (13).
When proportionally imbalanced (i.e., dysbiosis),
gut microbiota fails to exert beneficial interactions
with the host leading to alterations in the
host’s homeostasis (13). Probiotics are “live
microorganisms that, when administered in
adequate amounts, confer a health benefit on
the host” (8). Inhabiting the gastrointestinal tract,
probiotics outnumber the pathogens leading
to the eventual amelioration in the epithelial
barrier, immunomodulation, and production of
the short-chain fatty acids and vitamins (13-
15). Additionally, probiotics potentially target
organs besides the gastrointestinal tract,
mediated by immunoregulatory interactions
and neurotransmitter production (16, 17).
FamiLact is a synbiotic product containing
a broad spectrum of beneficial Lactobacillus
strains, Bifidobacterium breve/longum, and
Streptococcus thermophiles accompanied
by fructooligosaccharides as prebiotics, “a
substrate that is selectively utilized by host
microorganisms conferring a health benefit”
(18). The prebiotic content of the synbiotics,
designated to promote the survival of probiotic
strains in the gastrointestinal tract, synergically
provides better functionality compared to the
probiotic or prebiotic sole products (19).
To date, studies addressing the association
between probiotic administration and sperm
quality consist of few animal models and two
exclusive studies recruiting humans as subjects.
Although distinctive in design, these works share
results in favor of probiotic supplementation
regarding the enhancement in conventional
semen parameters (6, 7, 20-24). Likewise, in our
controlled clinical trial on men with idiopathically
impaired sperm analysis, we noticed a significant
increase in sperm concentration, motility, and
normal morphology following an 80-day course
of FamiLact supplementation. Consistent with
our results, Valcarce and colleagues indicated an
intense sixfold improvement in the sperm motility
applying Lactobacillus rhamnosus CECT8361
and Bifidobacterium longum CECT7347 as the
probiotic strains in 9 asthenozoospermic patients
(7). Similarly, in a randomized clinical trial study
consisting of 20 Flortec- and 21 placebo- (starch)
receivers, Maretti and colleagues underlined
a significant increase in the mean sperm
progressive motility, as well as concentration,
normal morphology, total count, and semen
volume in the case subpopulation after six
months of medication, while the before/after
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values did not differ significantly in the control
group (6).
Besides, in light of the growing evidence,
OS continues to strengthen its position as
the dominant etiology behind idiopathic male
infertility. Today, 30-80% of infertile men possess
relatively increased seminal ROS levels (3,
25). Recently, Agarwal and colleagues have
suggested a new terminology regarding the
association between infertility and OS-male
oxidative stress infertility (MOSI) - describing
the coexistence of impairment in semen
characteristics and OS in infertile men, many
of which were diagnosed with idiopathic male
infertility (3). Sperm DNA damage is among the
several mechanisms by which OS may impair
sperm’s fertilizing capability (25, 26). Damaged
DNA may further impair the implantation and
development of the resultant embryo, and
alter pregnancy and live birth rates (26). In
the present study, we detected a significant
decrease in DNA fragmentation index in both the
FamiLact and placebo receivers (Figure 2). The
observed alleviation in the DNA damage among
the control group may be explained by plausible
collateral supplementation, which may have been
concealed from the research team; similarly, the
analysis has revealed an almost-significant
increase in the mean sperm concentration
among the placebo receivers. However, the
reduction in DNA damage was dominantly more
significant in the FamiLact group (p = 0.005
vs. p = 0.03). Consistent with our result, the
two mentioned trials observed similar results
regarding DNA damage, albeit performing the
analysis on confined numbers of the participants
(Maretti and colleagues: n = 4; Valcarce and
colleagues: n = 6-8) (6, 7). To acknowledge the
interactions behind the association between
synbiotic supplementation and DNA integrity,
we monitored the alterations in the protamine
content of the sperm chromatin. Protamine is a
positively charged nuclear protein that replaces
sperm nucleo-histones throughout a complicated
process amid spermatogenesis leading to
favorable condensation of the sperm genetic
material (27). Condensed sperm chromatin is less
vulnerable to damage, namely fragmentation
(28). Utilizing the CMA3 staining technique, we
observed a minimal non-significant decrease in
protamine deficiency (i.e., CMA3 positivity) after
the intervention (p = 0.11). This finding suggests
that the resultant decline in DNA fragmentation
following probiotic administration may not be
mediated by increment in the protamine content,
supporting the OS hypothesis as the underlying
mechanism.
FamiLact contains different strains of
lactobacilli (L. rhamnosus, L. casei, L. bulgaricus,
and L. acidophilus) and bifidobacteria (B. breve,B.
longum). Evidence on OS-diminishing capabilities
of probiotics is emerging (29, 30). However,
such traits may be attributed to specific strains.
Of note, lactobacilli and bifidobacteria enhance
total antioxidant capacity and reduce markers
of the systemic OS through several possible
mechanisms, namely scavenging ROS or acting
as a metal chelator (29). As demonstrated by a
mice model study, probiotic supplementation may
subside the free radical content of the seminal
fluid, leading to the consequent alleviation in
OS and eventual reduction in the spermic DNA
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damage (31). Consistent with this finding, we
observed a significant decline in the percentage
of sperm lipid peroxidation - as an indicator
for the extent of OS-induced damage - in the
FamiLact group after medication (p = 0.02).
5. Conclusion
FamiLact administration improves semen
parameters, namely concentration, motility, and
abnormal morphology, and reduces sperm DNA
damage, possibly through alleviating OS state in
the seminal fluid. Accordingly, synbiotic products
-or more precisely, FamiLact- could be considered
as a safe and affordable treatment for idiopathic
male infertility. However, further investigation
on pregnancy outcomes of synbiotic-treated
patients may shed light on the fertility-related
practical capabilities of such products.
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